Join us for an exclusive interview with Gareth Sheridan, CEO and Co-Founder of Nutriband Inc. (NASDAQ: NTRB), in what may be one of his final interviews before temporarily stepping aside to run for President of Ireland.

We dive deep into the company's groundbreaking AVERSA technology and its path to becoming the world's first abuse-deterrent transdermal patch.

What You'll Learn:

• How AVERSA technology could revolutionize opioid safety while preserving patient access to critical pain medications
• The strategic significance of Nutriband's exclusive partnership with Kindeva Drug Delivery and what it means for commercialization timelines
• Why analysts project AVERSA Fentanyl could capture $200-500M in peak annual sales
• How the company's un ...